{"id":6762,"date":"2026-06-05T14:00:16","date_gmt":"2026-06-05T14:00:16","guid":{"rendered":"https:\/\/edren.org\/ren\/?page_id=6762"},"modified":"2026-06-05T14:10:56","modified_gmt":"2026-06-05T14:10:56","slug":"sglt2i-for-ckd-draft-june-26","status":"publish","type":"page","link":"https:\/\/edren.org\/ren\/handbook\/prescribing-handbook\/general-prescribing-notes\/sglt2i-for-ckd-draft-june-26\/","title":{"rendered":"SGLT2i for CKD (DRAFT June 26)"},"content":{"rendered":"

Please note this is still a DRAFT page.\u00a0 We have published so we can share internally and discuss at our Renal Unit meeting on Monday 8th June 2026.\u00a0 <\/span><\/strong>Although the information below is likely to be largely accurate, please ignore until we have approved the final version.\u00a0\u00a0<\/span><\/h4>\n

 <\/p>\n

SGLT2 inhibitors (‘flozins’) in CKD<\/h1>\n

SGLT2 inhibitors (SGLT2is) are powerful disease-modifying agents in Chronic Kidney Disease (CKD).\u00a0 They reduce the risk of kidney failure<\/strong>\u00a0and reduce cardiovascular disease <\/strong>(heart failure and CV death).\u00a0 They are appropriate for many patients with CKD but will require some individualised decision making (see below).<\/p>\n

 <\/p>\n

Quick decision tool<\/h3>\n\n\n\n\n\n\n\n\n
Patient profile<\/span><\/th>\neGFR threshold (ml\/min\/1.73 m2<\/sup>)<\/span><\/th>\nuACR threshold (mg\/mmol)<\/span><\/th>\nstrategy<\/span><\/th>\n<\/tr>\n<\/thead>\n
CKD & T2DM<\/span><\/td>\n> 15<\/span><\/td>\nany level<\/span><\/td>\noffer SGLT2i (strong<\/strong> recommendation)<\/span><\/td>\n<\/tr>\n
CKD without diabetes & heavy albuminuria<\/span><\/td>\n> 15<\/span><\/td>\n> 25<\/span><\/td>\noffer SGLT2i (strong<\/strong> recommendation)<\/span><\/td>\n<\/tr>\n
CKD without diabetes & little \/ no albuminuria<\/span><\/td>\n20 – 45<\/span><\/td>\n< 25<\/code><\/span><\/td>\noffer SGLT2i (slightly weaker<\/strong> recommendation)<\/span><\/td>\n<\/tr>\n
symptomatic heart failure<\/span><\/td>\n> 15<\/span><\/td>\nany level<\/span><\/td>\noffer SGLT2i (strong<\/strong> recommendation)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Notes:<\/strong><\/em><\/p>\n